HEXO Corp., through its subsidiaries, produces, markets, and sells cannabis in Canada.
+ 1 more risk
Mediocre balance sheet and slightly overvalued.
Share Price & News
How has HEXO's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 74H's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: 74H underperformed the German Pharmaceuticals industry which returned 7% over the past year.
Return vs Market: 74H underperformed the German Market which returned 8.1% over the past year.
Price Volatility Vs. Market
How volatile is HEXO's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is HEXO undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 74H (€0.58) is trading below our estimate of fair value (€0.63)
Significantly Below Fair Value: 74H is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: 74H is unprofitable, so we can't compare its PE Ratio to the XE Pharmaceuticals industry average.
PE vs Market: 74H is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 74H's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 74H is good value based on its PB Ratio (0.6x) compared to the DE Pharmaceuticals industry average (3.3x).
How is HEXO forecast to perform in the next 1 to 3 years based on estimates from 15 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 74H is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 74H is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 74H is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 74H's revenue (38.8% per year) is forecast to grow faster than the German market (5.8% per year).
High Growth Revenue: 74H's revenue (38.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 74H is forecast to be unprofitable in 3 years.
How has HEXO performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 74H is currently unprofitable.
Growing Profit Margin: 74H is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 74H is unprofitable, and losses have increased over the past 5 years at a rate of 90.7% per year.
Accelerating Growth: Unable to compare 74H's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 74H is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (11.2%).
Return on Equity
High ROE: 74H has a negative Return on Equity (-76.58%), as it is currently unprofitable.
How is HEXO's financial position?
Financial Position Analysis
Short Term Liabilities: 74H's short term assets (CA$259.5M) exceed its short term liabilities (CA$44.6M).
Long Term Liabilities: 74H's short term assets (CA$259.5M) exceed its long term liabilities (CA$101.5M).
Debt to Equity History and Analysis
Debt Level: 74H's debt to equity ratio (14.4%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if 74H's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 74H has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 74H has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is HEXO current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 74H's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 74H's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 74H's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 74H's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 74H's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Sébastien St-Louis (36 yo)
Mr. Sébastien G. St-Louis is the Co-Founder of HEXO Corp. (formerly known as The Hydropothecary Corporation) and has been its Chief Executive Officer, President and Director since August 13, 2013. Mr. St-L ...
CEO Compensation Analysis
Compensation vs Market: Sébastien's total compensation ($USD6.62M) is above average for companies of similar size in the German market ($USD995.99K).
Compensation vs Earnings: Sébastien's compensation has increased whilst the company is unprofitable.
|Chief Financial Officer||0.83yr||CA$3.03m||no data|
|General Counsel||2.42yrs||CA$1.20m||no data|
|Chief People Officer||1.92yrs||CA$1.27m||no data|
|Chief Operating Officer||1.25yrs||no data||no data|
|Manager of Financial Reporting & Investor Relations||no data||no data||no data|
|Director of Customer Experience & Compliance||no data||no data||no data|
|Vice President of Communication||1.58yrs||no data||no data|
|Vice-President of Sales||2.42yrs||no data||no data|
|Chief Development Officer||no data||CA$407.09k||no data|
|Senior Vice President of Procurement||no data||no data||no data|
Experienced Management: 74H's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
|Independent Chairman of the Board||no data||CA$600.75k||0.50% |
|Independent Director||5.75yrs||CA$534.55k||no data|
|Independent Director||3.75yrs||CA$562.69k||3.11% |
|Co-Founder & Director||7yrs||CA$538.91k||0.49% |
Experienced Board: 74H's board of directors are considered experienced (6.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: 74H insiders have sold more shares than they have bought in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 120.3%.
HEXO Corp.'s company bio, employee growth, exchange listings and data sources
- Name: HEXO Corp.
- Ticker: 74H
- Exchange: DB
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$426.550m
- Listing Market Cap: CA$270.583m
- Shares outstanding: 463.64m
- Website: https://www.hexocorp.com
Number of Employees
- HEXO Corp.
- 490 Boulevard Saint-Joseph
- Suite 204
- J8Y 3Y7
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|HEXO||TSX (The Toronto Stock Exchange)||Yes||Common Shares||CA||CAD||Mar 2017|
|HEXO||NYSE (New York Stock Exchange)||Yes||Common Shares||US||USD||Mar 2017|
|74H||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Mar 2017|
HEXO Corp., through its subsidiaries, produces, markets, and sells cannabis in Canada. It offers dried cannabis under the Time of Day and H2 lines; Elixir, a cannabis oil sublingual mist product line; and ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/08/09 20:53|
|End of Day Share Price||2020/08/07 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.